Medicago, Inc.
1020, route de l'Église
Sainte-Foy
Quebec
G1V 3V9
Canada
Fax: 418-658-6699
Website: http://www.medicago.com/
Email: rh-hr@medicago.com
144 articles with Medicago, Inc.
-
Medicago begins Phase I clinical trials for its COVID-19 vaccine candidate
7/14/2020
Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers
-
It has already administered the first doses of the candidate in healthy human subjects, and the company intends to initiate a Phase II/III trial this coming October.
-
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
7/7/2020
GSK and Medicago today announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago's recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK's pandemic adjuvant system.
-
GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
-
Medicago announces positive results in animal trials for its vaccine candidate against COVID-19
5/14/2020
Medicago, a biopharmaceutical company headquartered in Quebec City, announced that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice.
-
Government of Quebec providing $7 million towards Medicago's COVID-19 vaccine development
3/23/2020
Quebec City biopharmaceutical company moving towards testing stages of COVID-19 vaccine candidate
-
Canada’s Medicago announced Thursday it has successfully produced a Virus-Like Particle of the coronavirus just 20 days after obtaining the SARS-CoV-2 gene. The company is now focused on developing a vaccine for COVID-19, the virus caused by SARS-CoV-2.
-
Medicago Announces Production of a Viable Vaccine Candidate for COVID-19
3/12/2020
The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology
-
Medicago Awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress
4/25/2019
Medicago announced that its proprietary plant-based production platform, Proficia® was named "Best New Vaccine Technology/platform" at the World Vaccine Congress in Washington, D.C., attended by 1,500 participants including key opinion leaders from the vaccine industry.
-
Medicago Announces Phase III Study Of VLP Quadrivalent Influenza Vaccine
9/26/2017
-
Medicago Engaged By The Canadian Government To Develop Ebola Monoclonal Antibodies
10/29/2015
-
Medicago's $245 Million Facility Will Create 200 New Jobs, 40 Million New Vaccine Doses
5/20/2015
-
Medicago, Inc. Awarded A Contract By The U.S. Department Of Health And Human Services To Explore Alternate Production Methods For Ebola Antibodies
2/24/2015
-
Medicago, Inc. Awarded A Contract By The U.S. Department Of Health And Human Services To Explore Alternate Production Methods For Ebola Antibodies
2/24/2015
-
Company Reps From Biogen Idec, Inc. (Massachusetts) And Medicago, Inc. Talk Jobs At Biotech Center Panel
4/30/2014
-
Mitsubishi Tanabe Pharma Corporation Completes Acquisiton of Medicago, Inc.
9/18/2013
-
Medicago, Inc. Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement With Mitsubishi Tanabe Pharma Corporation
9/12/2013
-
Medicago, Inc. Shareholders Approve Arrangement Wth Mitsubishi Tanabe Pharma Corporation
8/30/2013
-
Medicago, Inc. Announces Leading Independent Proxy Firms Recommend Voting in Favour of the Arrangement With Mitsubishi Tanabe Pharma Corporation
8/20/2013
-
Medicago, Inc. Announces 2013 Second Quarter Financial Results
8/12/2013